During the last session, Galectin Therapeutics Inc (NASDAQ:GALT)’s traded shares were 0.39 million, with the beta value of the company hitting 0.78. At the end of the trading day, the stock’s price was $2.51, reflecting an intraday gain of 2.45% or $0.06. The 52-week high for the GALT share is $3.90, that puts it down -55.38 from that peak though still a striking 70.92% gain since the share price plummeted to a 52-week low of $0.73. The company’s market capitalization is $158.86M, and the average intraday trading volume over the past 10 days was 0.52 million shares, and the average trade volume was 597.68K shares over the past three months.
Galectin Therapeutics Inc (NASDAQ:GALT) trade information
Galectin Therapeutics Inc (GALT) registered a 2.45% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.45% in intraday trading to $2.51, hitting a weekly high. The stock’s 5-day price performance is 15.14%, and it has moved by 87.31% in 30 days. Based on these gigs, the overall price performance for the year is 94.57%. The short interest in Galectin Therapeutics Inc (NASDAQ:GALT) is 8.95 million shares and it means that shorts have 56.27 day(s) to cover.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -23.89%. While earnings are projected to return 11.84% in 2025, the next five years will return 5.57% per annum.
GALT Dividends
Galectin Therapeutics Inc is due to release its next quarterly earnings on 2025-May-15. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Galectin Therapeutics Inc (NASDAQ:GALT)’s Major holders
Galectin Therapeutics Inc insiders own 30.44% of total outstanding shares while institutional holders control 15.78%, with the float percentage being 22.68%. VANGUARD GROUP INC is the largest shareholder of the company, while 120.0 institutions own stock in it. As of 2024-06-30, the company held over 2.12 million shares (or 3.4002% of all shares), a total value of $4.78 million in shares.
The next largest institutional holding, with 1.56 million shares, is of BLACKROCK INC.’s that is approximately 2.5128% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.53 million.
Also, the Mutual Funds coming in first place with the largest holdings of Galectin Therapeutics Inc (GALT) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . Data provided on Mar 31, 2025 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 1.39 shares. This amounts to just over 2.19 percent of the company’s overall shares, with a $3.48 million market value. The same data shows that the other fund manager holds slightly less at 670.16, or about 1.06% of the stock, which is worth about $1.68 million.
